Psyence Biomedical Ltd PBM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.87
- Day Range
- $2.83–2.96
- 52-Week Range
- $1.92–468.36
- Bid/Ask
- $3.00 / $3.08
- Shares Outstanding
- 3.81M
- Market Cap
- $11.02M
- Volume/Avg
- 410,671 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 12
- Website
- https://www.psyence.com
Valuation
|
Metric
|
PBM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.42 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PBM
|
|---|---|
Quick Ratio | 12.53 |
Current Ratio | 14.62 |
Interest Coverage | −755.12 |
Quick Ratio
PBM
Profitability
|
Metric
|
PBM
|
|---|---|
Return on Assets (Normalized) | −44.07% |
Return on Equity (Normalized) | −51.58% |
Return on Invested Capital (Normalized) | −47.93% |
Return on Assets
PBM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!t<&fYR | LOCK|#^G>% | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>Gr<mCY | LOCK|>#Hy | $70B | |||
| argenx SE ADR
ARGX
| LOCK|rVN#>Wj | LOCK|SH | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%^#y#T | LOCK|>F?< | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>@X?dz | LOCK|qY> | $37B | |||
| Moderna Inc
MRNA
| LOCK|$G&$hd | LOCK|!m | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^bb?LF?^ | LOCK|n>@g | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|&Bw^N! | LOCK|Nr$ | $23B | |||
| Incyte Corp
INCY
| LOCK|S&^Rwp% | LOCK|>Sf | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|%n&&m&j | LOCK|cT | $16B |
United States